QZQi Zhou

Qi Zhou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qi Zhou has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Relationship Between the eTICI Score Before Randomization and 90-Day Outcome: A Post Hoc Analysis of ANGEL-TNK Trial

    by Xuelei Zhang, Xin Tong, Gang Luo, Ligang Song, Dapeng Sun, Wenhuo Chen, Xiaoxi Yao, Qi Zhou, Shuo Li, Zhongrong Miao, et al.

    BACKGROUND: Successful thrombectomy recanalization combined with intraarterial thrombolysis showed potential benefits in achieving excellent outcomes in recent trials, but the results were inconsistent. We performed this study to investigate the efficacy and safety of interarterial thrombolysis in patients stratified by expanded Thrombolysis in Cerebral Infarction (eTICI) score after thrombectomy. METHODS: This is a prespecified secondary analysis of the ANGEL-TNK trial (Intraarterial Recombinant Human TNK-tPA Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization; multicenter, randomized, open-label, blinded end point). Participants who had anterior circulation large artery occlusion were enrolled and randomized (1:1) to interarterial tenecteplase (TNK; 0.125 mg/kg) or standard medical management after eTICI 2b50 to 3 reperfusion. The primary outcome was the rate of 90-day modified Rankin Scale score 0 to 1. Safety outcomes included symptomatic intracranial hemorrhage and any intracranial hemorrhage within 48 hours, and death within 90 days. RESULTS: Of the 253 patients enrolled, 164 were in the eTICI 2b50 to 67 group, and 89 were in the eTICI 2c to 3 group. Interarterial TNK after EVT was associated with a higher rate of modified Rankin Scale score 0 to 1 at 90 days in patients with an eTICI score of 2b50 to 67 (39 [44.8%] versus 15 [19.5%]; relative risk, 2.08 [95% CI, 1.35–3.21]; P =0.001), but not in those with eTICI 2c to 3 (12 [30.8%] versus 19 [38.0%]; relative risk, 0.84 [95% CI, 0.29–2.44]; P =0.749). In the eTICI 2c to 3 group, interarterial TNK resulted in more cases of any intracranial hemorrhage within 48 hours (13 [33.3%] versus 10 [20.0%]; relative risk, 1.70 [95% CI, 1.05–2.77]; P =0.032), but not in the eTICI 2b50 to 67 group (18 [20.7%] versus 25 [32.5%]; relative risk, 0.65 [95% CI, 0.34–1.22]; P =0.176). The difference was not observed in symptomatic intracranial hemorrhage within 48 hours or death within 90 days in either group. CONCLUSIONS: Interarterial TNK after EVT provides additional benefits for excellent outcomes, defined as a modified Rankin Scale score of 0 to 1 at 90 days, in patients with an eTICI score of 2b50 to 67, but not in those with eTICI 2c to 3. It increases the risk of any intracranial hemorrhage in patients with an eTICI score of 2c to 3, without elevating the risk of symptomatic intracranial hemorrhage or death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05624190.

  • Open Access

    The lancet commission obesity categories, excess adiposity, and BMI discordance in urban Chinese adults: a cross-sectional survey in Beijing

    by Zhenyu Liu, Wendong Wang, Wendong Cao, Qing Yao, Qi Zhou

    Introduction: BMI remains central to obesity surveillance, but it does not distinguish excess adiposity from obesity-related disease. The Lancet Commission framework first confirms excess adiposity and then classifies individuals as having no obesity, preclinical obesity, or clinical obesity. We applied this framework using China-specific anthropometric cut points to estimate Lancet obesity categories, characterize clinical obesity, assess discordance with BMI categories, and examine related demographic and lifestyle factors in urban Chinese adults. Methods: We analyzed data from the 2024 Haidian Chronic Disease and Risk Factor Surveillance, a stratified multistage probability cluster survey in urban Beijing. Excess adiposity was confirmed using BMI, waist circumference, and waist-to-height ratio. Lancet obesity categories were assigned after assessment of obesity-related complications. Survey-weighted prevalence estimates and ordinal logistic regression were used. Results: The final analytic sample included 8,130 adults aged 18–79 years. The weighted prevalence of excess adiposity was 41.2%, and the prevalence of clinical and preclinical obesity was 37.3% and 3.9%, respectively. The most frequent complications among participants with clinical obesity were metabolic impairment and hypertension. BMI categories were substantially discordant with Lancet obesity categories: clinical obesity was present in 5.3% of participants with BMI 2 and 41.6% of those with BMI 24.0–27.9 kg/m 2 , whereas 3.4% of participants with BMI ≥28 kg/m 2 had no obesity. Female sex was associated with lower odds of being in a higher ordered Lancet obesity category (OR, 0.46; 95% CI, 0.40–0.53). Discussion: A substantial clinical obesity burden and marked discordance with BMI categories were identified in urban Beijing adults when applying the Lancet framework. These findings support complementing BMI with assessment of excess adiposity and obesity-related complications in chronic disease surveillance.

  • Open Access

    Magnetocardiography for Exploratory Risk Stratification in Patients With Three‐Vessel Coronary Artery Disease: A Single‐Center Prospective Cohort Study

    by Ziyu An, Shipan Wang, Min Zhang, Mingduo Zhang, Lanxin Feng, Shuwen Yang, Qi Zhou, Haiyang Hu, Chenchen Tu, Hongjia Zhang, et al.

    Background and Aims: Patients with three‐vessel coronary artery disease (3V‐CAD) remain at heterogeneous risk for major adverse cardiovascular and cerebrovascular events (MACCE) after revascularization. Magnetocardiography (MCG) is a noncontact and radiation‐free technique that may capture electrophysiological abnormalities not reflected by anatomical risk scores. This study evaluated the exploratory prognostic value of MCG‐derived parameters in patients with 3V‐CAD. Methods: This single‐center prospective cohort study included 544 patients with 3V‐CAD who underwent coronary revascularization. MCG recordings were obtained before revascularization using a 36‐channel optically pumped magnetometer‐based system. The primary endpoint was MACCE, defined as cardiac death, stroke, myocardial infarction, or unplanned revascularization. Cox regression models were constructed using clinical variables, SYNTAX score, and an MCG composite variable. Model performance was assessed using discrimination, calibration, decision curve analysis, and bootstrap internal validation. Results: During a median follow‐up of 725 days, 37 patients (6.8%) experienced MACCE. The SYNTAX score was independently associated with MACCE after adjustment for clinical variables and MCG score (hazard ratio [HR], 1.08; 95% confidence interval [CI], 1.04–1.12; p < 0.001). The MCG composite variable was also associated with MACCE after adjustment for clinical variables and SYNTAX score (HR, 2.74; 95% CI, 1.57–4.79; p < 0.001). Model discrimination increased from 0.596 for clinical variables alone to 0.682 after adding SYNTAX score and to 0.727 after adding MCG. However, the improvement from the clinical + SYNTAX model to the MCG‐added model was not statistically significant ( p = 0.17). Bootstrap validation showed an optimism‐corrected C ‐index of 0.672. Conclusion: MCG‐derived parameters were associated with MACCE and may provide complementary electrophysiological information for exploratory risk stratification in patients with 3V‐CAD after revascularization. Larger multicenter studies with external validation are needed to confirm its complementary prognostic value. Trial Registration: Chinese Clinical Trial Registry identifier: ChiCTR2200066942

  • Efficacy and Safety of Dual Antiplatelet Treatment up to 72 Hours in Acute Ischemic Stroke Stratified by Glycemic Status

    by Qi Zhou, Ying Gao, Weiqi Chen, S. Claiborne Johnston, Pierre Amarenco, Philip M. Bath, Xuan Wang, Hongyi Yan, Tingting Wang, Yingying Yang, et al.

    Objective: The objective was to investigate the efficacy and safety of clopidogrel‐aspirin versus aspirin alone in patients after ischemic stroke by glycemic status using data from the Intensive Statin and Antiplatelet Therapy for Acute High‐risk Intracranial or Extracranial Atherosclerosis (INSPIRES) trial.Methods: Patients with mild ischemic stroke or high‐risk transient ischemic attack (TIA) were randomized to clopidogrel‐aspirin or aspirin alone. They were categorized into 3 subgroups according to glycemic status based on medical history and diagnosis by a clinician during hospitalization: without type 2 diabetes mellitus, with newly diagnosed type 2 diabetes, and with a history of type 2 diabetes mellitus. The primary efficacy and safety outcomes were new stroke and moderate‐to‐severe bleeding risk within 90‐day follow‐up.Results: A total of 6,100 patients were enrolled (3,050 in each arm), with a median age of 65 years (interquartile range [IQR], 57–71) and 2,185 female (35.8%). Clopidogrel‐aspirin treatment was associated with a reduction in recurrent stroke compared with aspirin alone in patients without type 2 diabetes mellitus (6.3% vs 8.4%; hazard ratio [HR], 0.75; 95% confidence interval [CI], 0.59–0.94; p = 0.01) and those with newly diagnosed type 2 diabetes mellitus (5.8% vs 13.0%; HR, 0.30; 95% CI, 0.14–0.66; p = 0.002), but not in those with a history of type 2 diabetes mellitus (10.0% vs 9.9%; HR, 0.98; 95% CI, 0.72–1.33; p = 0.88) (p for interaction = 0.03). Moderate‐to‐severe bleeding events did not differ significantly by treatment across glycemic subgroups.Interpretation: In the INSPIRES trial, patients without or with type 2 diabetes mellitus derived greater benefit from clopidogrel‐aspirin than those with a history of type 2 diabetes mellitus after mild ischemic stroke or high‐risk TIA.Trial Registration: INSPIRES, NCT03635749. Registered 15 August 2018, https://clinicaltrials.gov/search?cond=NCT03635749. ANN NEUROL 2025;98:174–182


  • Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke Stratified by Risk Profile: A Post Hoc Analysis

    by Yanli Zhang, Xuan Wang, Ying Gao, Weiqi Chen, S. Claiborne Johnston, Pierre Amarenco, Philip M. Bath, Hongyi Yan, Tingting Wang, Yingying Yang, et al.

    BACKGROUND: Risk profile of recurrence may influence the effect of antiplatelet therapy. This study aimed to evaluate the efficacy and safety of clopidogrel-aspirin initiated within 72 hours after symptom onset for acute mild stroke or high-risk transient ischemic attack stratified by risk profile. METHODS: This is a secondary post hoc analysis of the INSPIRES (Intensive Statin and Antiplatelet Therapy for Acute High-risk Intracranial or Extracranial Atherosclerosis) randomized clinical trial that enrolled patients 35 to 80 years old with acute mild ischemic stroke or high-risk transient ischemic attack between 2018 and 2022. Patients were stratified into different groups based on the Essen Stroke Risk Score (ESRS) and modified ESRS. The primary efficacy outcome was any new stroke within 90 days. The primary safety outcome was moderate-to-severe bleeding within 90 days. RESULTS: Among 6100 patients (3050 each in the clopidogrel-aspirin group and aspirin group), the median age was 65 years (interquartile range, 57–71 years), and 3915 (64.2%) were male. Clopidogrel-aspirin was associated with a reduced risk of new stroke in patients with an ESRS of P interaction =0.07). Similar results were found in patients stratified by modified ESRS (modified ESRS P interaction =0.01). The association between antiplatelet therapy and the moderate-to-severe bleeding did not differ across risk profile subgroups (ESRS of P interaction =0.21; modified ESRS of P interaction =0.85). CONCLUSIONS: This post hoc analysis of the INSPIRES trial showed that patients with a low level of risk profile assessed by ESRS received greater benefit from clopidogrel-aspirin initiated within 72 hours after symptom onset than aspirin alone. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03635749.


  • Open Access

    Characteristics, temporal trends and outcomes of intravenous thrombolysis in Chinese patients aged>80 years who had a stroke

    by Changsheng Li, Yingyu Jiang, Hong-Qiu Gu, Meng Wang, Zimo Chen, Xin Yang, Qi Zhou, Xia Meng, Chunjuan Wang, Zixiao Li

    Background and purpose To date, no large cohort study has investigated the effects of intravenous thrombolysis (IVT) in Chinese patients aged over 80 years who had a stroke. This study aimed to assess the trends in the use of alteplase, the clinical characteristics and the outcomes of Chinese patients aged above 80 years who had an acute ischaemic stroke. Methods Data for this analysis were obtained from the China Stroke Center Alliance programme, a nationwide, multicentre, prospective registry encompassing 1751 hospitals across 31 provinces, covering the period from 1 January 2018 to 14 December 2022. The primary outcome was defined as a modified Rankin Scale (mRS) Score of 0–2 at discharge. Secondary outcomes included an mRS Score of 0–1 and independent ambulation on discharge. Safety outcomes assessed were in-hospital mortality and symptomatic intracranial haemorrhage (sICH). Results Out of 30 902 patients over 80 years old who qualified for thrombolysis, 8673 (median age (IQR), 84 (82–87) years) received alteplase treatment. Patients administered alteplase demonstrated improved short-term functional outcomes, such as an mRS Score of 0–2 (adjusted OR (aOR) 1.12, 95% CI, 1.06 to 1.18, pConclusions IVT with alteplase in elderly patients who had a stroke resulted in improved short-term functional outcomes without elevating the risk of in-hospital mortality. Nonetheless, this population remains at a higher risk of sICH.


  • Associations of noninsulin-based insulin resistance indices with presence and extent of multiterritorial atherosclerosis: A cross-sectional study

    by Yanli Zhang, Mengxing Wang, Xueli Cai, Aoming Jin, Jing Jing, Suying Wang, Xia Meng, Shan Li, Qi Zhou, Xuan Wang, et al.


  • Associations between Adipose Tissue-Specific Insulin Resistance and Atherosclerotic Plaques and Burden in Community-Based Population

    by Qi Zhou, Xueli Cai, Aoming Jin, Jing Jing, Mengxing Wang, Suying Wang, Lerong Mei, Xia Meng, Shan Li, Tiemin Wei, et al.

    Background: We aimed to examine the association between adipose tissue-specific insulin resistance and atherosclerotic burden and plaques in intracranial, extracranial, and coronary arteries in community residents without diabetes. Methods: Adipose tissue-specific insulin resistance index (Adipo-IR) was calculated by fasting serum insulin and free fatty acids and categorized into 4 groups according to the quartiles. The 3.0 T magnetic resonance imaging scanner was used to assess intracranial and extracranial atherosclerotic plaques, while computed tomography angiography was used to assess coronary atherosclerotic plaques. Intracranial, extracranial, and coronary atherosclerotic burden was assessed by segmental stenosis segment scores of the corresponding arterial segments, respectively. Binary and ordinal logistic regression models were utilized to investigate the relationship of Adipo-IR with the presence of atherosclerotic plaques and atherosclerotic burden. Results: Of 2,719 participants (mean [standard deviation] age, 60.9 [6.6] years; 1,441 [53.0%] women), the prevalence of intracranial atherosclerotic plaques, extracranial atherosclerotic plaques, and coronary plaques were 432 (15.9%), 975 (35.9%), and 1,160 (42.7%), respectively. Compared with individuals with the lowest quartile, participants with the fourth quartile of the Adipo-IR were associated with intracranial atherosclerotic burden (common odds ratio [cOR]: 1.35; 95% confidence interval [CI]: 0.99–1.82), coronary plaque (odds ratio [OR]: 1.45; 95% CI: 1.15–1.83), and segment stenosis score (cOR: 1.44; 95% CI: 1.15–1.81) after adjustment for age, sex, and current smoking. Conclusion: Adipose tissue-specific insulin resistance is associated with atherosclerotic burden and plaques in intracranial and coronary arteries in Chinese community nondiabetic residents.


  • Open Access

    Comparison of stress hyperglycemia ratio and glycemic gap on acute ICH in‐hospital outcomes

    by Jia Zhang, Qian Zhang, Hongqiu Gu, Qi Zhou, Zixiao Li, Xingquan Zhao

    Objective: To compare the effect of different indicators on stress‐induced hyperglycemia for predicting in‐hospital outcomes of acute intracerebral hemorrhage.Methods: Using data from the Chinese Stroke Center Alliance database, which is a national, multicenter, prospective, and consecutive program. Stress‐induced hyperglycemia was described as glycemic gap (GG, defined as fasting blood glucose [FBG] minus estimated average blood glucose) and stress hyperglycemia ratio (SHR, defined as FBG‐to‐estimated average blood glucose ratio [SHR 1] or FBG‐to‐HbA1c ratio [SHR 2]). The primary outcome was in‐hospital mortality, and the second outcome was hematoma expansion.Results: A total of 71,333 patients with acute intracerebral hemorrhage were included. In multivariate analyses, the highest levels of GG (OR 1.68, 95% CI 1.12–2.51), SHR 1 (OR 1.73, 95% CI 1.15–2.60), and SHR 2 (OR 2.07, 95% CI 1.33–3.23) were associated with in‐hospital death (all the p trends 0.05) was related to hematoma expansion. No association between GG or SHR 1 and hematoma expansion was observed. The areas under the ROC curve of GG, SHR 1, and SHR 2 for in‐hospital mortality were 0.8808 (95% CI 0.8603–0.9014), 0.8796 (95% CI 0.8589–0.9002), and 0.8806 (95% CI 0.8600–0.9012). The areas under the ROC curve of SHR 2 for hematoma expansion were 0.7133 (95% CI 0.6964–0.7302).Interpretation: SHR (FBG‐to‐HbA1c ratio) was associated with both in‐hospital death and hematoma expansion in intracerebral hemorrhage, and might serve as an accessory indicator for the in‐hospital prognosis of intracerebral hemorrhage.